Clinical Oncology Pharmacist, Ann B. Barshinger Cancer Institute, Lancaster, Pennsylvania Mirtazapine is a tetracyclic antidepressant approved by the US Food and Drug Administration for the treatment ...

A study describes the generation of a new mouse model that could lead to a better understanding of the cachexia syndrome. A study published in Cell Reports Aug. 6 describes the generation of a new ...

Cachexia is a process that accompanies many chronic diseases, and consists of a combination of wasting of lean body mass, increased energy expenditure, and a paradoxical loss of appetite. Cachexia ...

In 2011, Laura Beaver did not let the growing tumor in her body dictate her life. She kept up her normal hourlong gym routine. She took weekend bike rides near her Washington state home. She did the ...

For this narrative review, peer-reviewed articles were searched on PubMed, clinical trials records were searched on clinicaltrials.gov, and records of digital measures submitted for regulatory ...

Cancer ravages both body and mind. If you've ever lost loved ones to the disease, you might recognize the physical and emotional changes cancer patients often endure during their final months. They ...

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...

Ponsegromab increased weight and activity levels in cachexia patients, confirming GDF-15 as a key driver and therapeutic target. Significant weight gain was observed in ponsegromab-treated groups ...

Cachexia is a paraneoplastic syndrome of unintentional adipose and muscle tissue wasting with severe impacts to functionality and quality of life. Although health inequities across minority and ...

INDIANAPOLIS--(BUSINESS WIRE)--Researchers will continue to explore the impact of Apexian’s target molecule, APX3330, on cancer cachexia with additional grant funding from the National Institutes of ...